Annual Dutch Diabetes Research Meeting 2016

Nederlandse Vereniging voor Diabetes Onderzoek (NVDO)
Nederlandse Associatie voor de Studie van Obesitas (NASO)
Netherlands Diabetes Epidemiology Study Group (NDESG)
Psychosocial Aspects of Diabetes (PSAD) Study Group
Nederlandse Vereniging voor Neurovasculaire Complicaties van Diabetes (NVCD)

1 - 2 December 2016
Hotel de Bilderberg, Oosterbeek
10.15-10.30 NVDO/NASO
PS1: Adipose Tissue Biology I
Chair: Gijs Goossens
Het Binnenhof

9.15-9.30: Y. Xin (Maastricht)
1. Longitudinal associations of the alternative and terminal pathways of complement activation with obesity: The CODAM study

9.30-9.45: M. Brom (Nijmegen)
2. Glucose uptake in visceral adipose tissue is decreased in obese type 2 diabetic subjects compared to healthy obese subjects, as measured by 18F-FDG PET/CT

9.45-10.00: K. Nahon (Leiden)
3. Unravelling the cause of the type 2 diabetes epidemic in South Asians: role for the endocannabinoid system?

10.00-10.15: E. Kuipers (Leiden)
4. Deraiment of the endocannabinoid system in diet-induced obesity starts in brown adipose tissue

10.15-10.30: H. v/d Zande (Leiden)
5. Helminth antigens improve insulin sensitivity in obese mice by promoting a STAT6-dependent type 2 immune response in white adipose tissue

10.15-10.30 NVDO/NASO
PS2: Cardiovascular Function and Biology I
Chair: Joris Hoeks
Bibliotheque

9.15-9.30: E. Manders (Eindhoven)
6. High-fat diet feeding in mice may partially protect the heart from pressure overload induced heart failure

9.30-9.45: D. van Moorsel (Maastricht)
7. Bcl gluocorticoid receptor polymorphism is not associated with arterial stiffening and cardiac structure and function: the Hoorn & CODAM studies

9.45-10.00: A. Emanuel (A’dam)
8. Relationships between type 2 diabetes, neuropathy and microvascular dysfunction: evidence from patients with chronic idiopathic axonal polyneuropathy

10.00-10.15: M. Muskiet (A’dam)
9. Renal Effects of DPP-4 Inhibitor Linagliptin versus SU-Derivative Glimepiride in Metformin-Treated Overweight Type 2 Diabetes Patients: An 8-week, Randomized, Double-Blind Trial

10.15-10.30: N. Koks (R’dam)
10. Glucose-dependent leukocyte activation in familial hypercholesterolemia

10.15-10.30 PSAD
PS3: PSAD
Chair: Giesje Nef
The Lacock Abbey

9.15-9.30: M. Eilander (Amsterdam)
11. Not parental well-being but parental diabetes behaviors and stress are related to glycemic control in youth with type 1 diabetes. Longitudinal data from the DINO study

9.30-9.45: L. Nguyen (Tilburg)
12. Emotional problems in adolescents with type 1 diabetes and their parents: Preliminary baseline results from the longitudinal Diabetes LEAP Study

9.45-10.00: C. Schmidt (A’dam)
13. Persons with diabetes from ethnic minorities differ in their vulnerability for emotional distress

10.00-10.15: B. Özcan (Rotterdam)
14. More diabetes distress in ethnic minorities

10.15-10.30: S. Westra (Leiden)
15. Depression and mortality among older adults with and without diabetes mellitus; 23 year after the start of the Longitudinal Aging Study Amsterdam

10.15-10.30 PSAD
PS4: metabolic risk factors for diabetes
Chair: René de Mutsert
The Oval Office

9.15-9.30: C. Ruijgrok (A’dam)
18. Quantifying the association of glycaemic measures and fasting insulin with incident type 2 diabetes - The Hoorn Study

9.30-9.45: V. Boersma (Leiden)
19. The role of adiponectin in the association between overall and visceral adiposity and insulin resistance: the NEO study

9.45-10.00: R. Noordam (Leiden)
20. Low-grade systemic inflammation and type 2 diabetes mellitus: A Mendelian randomization study

10.00-10.15: T. Mulder (Leiden)
21. The separate contributions of visceral fat and liver fat to the incidence of type 2 diabetes

10.15-10.30: M. Bos (Leiden)
22. Thyroid signaling, insulin resistance and type 2 diabetes mellitus: a Mendelian randomization study

10.15-10.30 NDESG

10.30-11.15 Coffee break
<table>
<thead>
<tr>
<th>Time</th>
<th>Session Title</th>
<th>Chair</th>
</tr>
</thead>
<tbody>
<tr>
<td>11.15-12.30</td>
<td>NVDO/NASO</td>
<td></td>
</tr>
<tr>
<td>11.15-12.30</td>
<td>PS6: Gastrointestinal and Liver Biology I</td>
<td>Emanuel Canfora</td>
</tr>
<tr>
<td></td>
<td>PS7: Life Style</td>
<td>Esther Phelix</td>
</tr>
<tr>
<td>11.15-11.30</td>
<td>S. Daemen (Maastricht)</td>
<td></td>
</tr>
<tr>
<td>11.15-11.30</td>
<td>A. Janssen (Wageningen)</td>
<td></td>
</tr>
<tr>
<td>11.30-11.45</td>
<td>I. Zwarts (Groningen)</td>
<td></td>
</tr>
<tr>
<td></td>
<td>M. Westra (Amsterdam)</td>
<td></td>
</tr>
<tr>
<td>12.00-12.15</td>
<td>V. Nies (Groningen)</td>
<td></td>
</tr>
<tr>
<td>12.15-12.30</td>
<td>P. de Groot (Amsterdam)</td>
<td></td>
</tr>
<tr>
<td></td>
<td>M. Westra (Amsterdam)</td>
<td></td>
</tr>
<tr>
<td>12.30-12.45</td>
<td>P. de Groot (Amsterdam)</td>
<td></td>
</tr>
<tr>
<td></td>
<td>M. Westra (Amsterdam)</td>
<td></td>
</tr>
<tr>
<td>11.15-12.30</td>
<td>NVCD</td>
<td>Edgar Peters</td>
</tr>
<tr>
<td>11.15-12.45</td>
<td>PS8</td>
<td></td>
</tr>
<tr>
<td>11.15-12.45</td>
<td>PSAD</td>
<td>Giesje Nef</td>
</tr>
<tr>
<td>11.15-12.45</td>
<td>PSAD (CNT’D)</td>
<td></td>
</tr>
<tr>
<td>11.15-12.30</td>
<td>PS9</td>
<td>Amber van der Heijden</td>
</tr>
<tr>
<td>11.15-12.30</td>
<td>NDESG</td>
<td></td>
</tr>
<tr>
<td>11.15-12.30</td>
<td>PS5 (CNT’D): KLINISCHE DIABETOLOGIE</td>
<td>Suat Simsek</td>
</tr>
<tr>
<td>11.15-11.45</td>
<td>Koen van Beers</td>
<td></td>
</tr>
<tr>
<td>11.15-12.30</td>
<td>Nel Geelhoed-Duyvenstijn</td>
<td></td>
</tr>
<tr>
<td>12.15-12.30</td>
<td>J. Kropp (A’dam)</td>
<td></td>
</tr>
</tbody>
</table>

**Thursday 1 December 11.15-12.30 Parallel sessions**

**NVDO/NASO**

11.15-11.30: A. Janssen (Wageningen)
25. Modulation of the gut microbiota affects the development of non-alcoholic fatty liver disease: a possible role for bile acids

11.30-11.45: I. Zwarts (Groningen)
26. Intestinal PPAR-delta protects against diet-induced obesity, insulin resistance and dyslipidemia and is required for ligand-stimulated HDL biogenesis

11.45-12.00: E. van den Berg (Groningen)
27. Prevalence and determinants of non-alcoholic fatty liver disease in Lifelines: a large Dutch population cohort

12.00-12.15: J. Hoogerland
28. Glucose-6-phosphate: a novel regulator of hepatic bile acid synthesis

12.15-12.30: V. Nies (Groningen)
29. The role of ERK signaling in the metabolic effects of FGF1 in vivo

12.30-12.45: P. de Groot (Amsterdam)
30. Gut microbiota, short-chain fatty acids and inflammatory characteristics in type 1 diabetes patients versus matched healthy controls

11.15-11.30: S. Daemen (Maastricht)
31. Differential changes in myocellular lipid droplet morphology between type 2 diabetes patients responsive or unresponsive to exercise training

11.30-11.45: J. Bolijn (Maastricht)
32. Sitting less versus more exercise on endothelial dysfunction in healthy, overweight subjects and subjects with type 2 diabetes

11.45-12.00: A. van Meijel (Nijmegen)
33. The effect of an automated bolus calculator on glucose variability and quality of life in people with diabetes treated with insulin pumps

12.00-12.15: K. Berk (Rotterdam)
34. Effect of body weight reduction on Lp(a) levels in obesity and type 2 diabetes

12.15-12.30: B. Duivivier (Maastricht)
35. Effects of interrupting sitting by light-intensity activities on insulin sensitivity, plasma lipids, cognition and mood

11.45-12.30: NVCD
36. Determinants of offloading in cast devices to reduce plantar pressure in the diabetic foot

12.15-12.30: S. van Steen (Amsterdam)
37. The effect of innovative footwear concepts on plantar pressure and patient satisfaction in high-risk diabetic patients

12.30-12.45: W. aan de Stegge (Amsterdam)
38. Prediction Model for Plantar Foot Ulcer Recurrence in High-Risk Diabetes Patients

12.45-13.00: R. Keukenkamp (Amsterdam)
39. Plantar foot pressures, footwear adherence, and ulcer recurrence in diabetic patients with Charcot foot deformity

11.15-11.30: R. Vos (Utrecht)
16. What determines treatment satisfaction of type 2 diabetes patients on insulin therapy from eight European countries?

11.30-11.45: E. de Koning (Leiden)
17. Personalised Diabetes Care: from diabetes monitoring to putting diabetes in a patient’s context

11.45-12.00: K. Smits (Groningen)
46. Association between prescribing quality indicators and intermediate outcomes in patients with type 2 diabetes

12.00-12.15: S. van Steen (Amsterdam)
47. The Hemoglobin Glycation Index as Predictor of Diabetes Related Complications in the AleCardio Trial

12.15-12.30: R. Vos (Utrecht)
44. Glucose regulation and use of glucose-lowering medication in the first 10 years after screen-detection of type 2 diabetes: findings from the ADDITION-Netherlands trial cohort

12.30-12.45: J. Zwaferink (Amsterdam)
45. Poor socio-economic status equals poor glycemic control? Data from the Dutch Diabetes Pearl cohort

12.45-12.00: K. Smits (Groningen)
48. Determinants of hypoglycaemia in a cohort of patients with type 2 diabetes

11.15-11.45: S. van Steen (Amsterdam)
49. Determinants of hypomagnesaemia in a cohort of patients with type 2 diabetes

11.30-11.45: A. Rutte (Amsterdam)
50. Poor socio-economic status equals poor glycemic control? Data from the Dutch Diabetes Pearl cohort

12.15-12.30: R. Vos (Utrecht)
51. Personalised Diabetes Care: from diabetes monitoring to putting diabetes in a patient’s context

12.30-12.45: J. Zwaferink (Amsterdam)
52. Prediction Model for Plantar Foot Ulcer Recurrence in High-Risk Diabetes Patients

12.45-13.00: R. Keukenkamp (Amsterdam)
53. Plantar foot pressures, footwear adherence, and ulcer recurrence in diabetic patients with Charcot foot deformity
### 12.30-13.00 Lunch break

### 13.30-13.45 NVDO/NASO

#### PS10: Gastrointestinal and Liver Biology II

Chair: Johan Jocken  
Het Binnenhof

**13.30-13.45: Z. Wang**  
(Groningen)  
49. Inhibition of intestinal inflammation by 5-ASA protects against the development of NAFLD in Mice

**13.45-14.00: N. Simons**  
(Maastricht)  
50. A common gene variant in glucokinase regulatory protein interacts with glucose metabolism on diabetic dyslipidemia: the combined CODAM and Hoorn studies

**14.00-14.15: E. Canfora**  
(Maastricht)  
51. Twelve-week supplementation of galacto-oligosaccharides increased bifidobacteria in obese prediabetic adults, whereas insulin sensitivity and energy metabolism were not changed

**14.15-14.30: Z. Li**  
(Leiden)  
52. Butyrate via the gut-brain neuronal circuit reduces appetite and activates brown adipose tissue

### 13.30-15.00 NVDO/NASO

#### PS11: Beta cell function and hypoglycemia

Chair: Maarten Brom  
Bibliotheque

**13.30-13.45: J. Ellenbroek**  
(Leiden)  
54. A-Kinase Anchoring Proteins in the Protection of Pancreatic Beta-cells from Cytokines

**13.45-14.00: W. Top**  
(Hoogeveen)  
55. Metformin and beta cell function in insulin-treated patients with type 2 diabetes: a randomized placebo-controlled 4.3 year trial

**14.00-14.15: G. Dharmadhikari**  
(Leiden)  
56. Effects of ageing on islet cell transcriptome signatures in mice

**14.15-14.30: J. Ratter**  
(Nijmegen/Wageningen)  
57. Pro-inflammatory effects of hypoglycemia in humans with or without diabetes

**14.30-14.45: L. Joosten**  
(Nijmegen)  
58. Non-invasive determination of the beta cell mass with 111In-exendin-3 in rodent models for spontaneous type 1 diabetes

**14.45-15.00: M. Greevenbroek**  
(Maastricht)  
59. Activation of the alternative pathway of complement, represented by factor Bb, is longitudinally associated with beta-cell conservation in type 2 diabetes: the CODAM study

### 13.30-14.45 NVCD

#### PS8: NVCD (CNT’D)

Chair: Nicolaas Schaper  
The Lacock Abbey

**13.30-13.45: O. Mennes**  
(Almelo)  
40. Assessment of Microcirculation in the Foot of People with Diabetes with Laser Speckle Contrast Imaging

**13.45-14.00 S. van Asten**  
(Amsterdam)  
41. Complications during the treatment of diabetic foot osteomyelitis

**14.00-14.15: L. Lavery**  
(Amsterdam)  
42. The use of Erythrocyte sedimentation rate and C-reactive protein to distinguish acute infection in patients with diabetic foot osteomyelitis

**14.15-14.45: Plenary lecture:**  
J. van Baal

### 13.30-14.45 NDESQ

#### PS12: LIFESTYLE RISK FACTORS FOR TYPE 2 DIABETES

Chair: Femke Rutters  
The Oval Office

**13.30-14.00:**  
Plenary Lecture: Sabita Soedamah-Muthu

**Food matrix relevance involving dairy products and diabetes?**

**14.00-14.15: L. Vissers**  
(Leiden)  
60. Is dairy product intake related to risk of type 2 diabetes? A pan-European Mendelian Randomisation study

**14.15-14.30: A. Koopman**  
(Amsterdam)  
61. The association between social jetlag, the metabolic syndrome and type 2 diabetes mellitus in a middle-aged population: the New Hoorn study

**14.30-14.45: E. Walaszczyzk**  
(Amsterdam)  
62. DNA methylation markers associated with type 2 diabetes and glycemic traits: preliminary results of a replication study in the Lifelines cohort

### 13.30-14.45 NVDO/NASO

#### PS13: Clinical session

Chair: Marten Engelse

**13.30-13.45: A. Kooy**  
(Hoogeveen)  
63. Metformin and pharmacogenetics: the efficacy of polymorphisms on daily dose of insulin, glycemic control and metformin plasma levels - a post-hoc analysis of a 4.3 year RCT

**14.00-14.15: J. de Maar**  
(Zwolle)  
64. Once daily NPH insulin results in better glycemic control than short-acting sliding scale insulin in patients with glucocorticoid-induced hyperglycemia during chemotherapy

**14.00-14.15: M. Nijhof**  
(Leiden)  
65. Diazoxide to improve islet transplant survival improves survival in vitro and functionality in vivo

**14.15-14.30: B. Uitbeijerve**  
(Leiden)  
66. Fasting relative proinsulin secretion as a marker for B-cell secretory strain and B-cell function in patients with type 1 diabetes

**14.30-14.45: J. Doppenberg**  
(Leiden)  
### Thursday 1 December 15.15-16.15 Parallel sessions

<table>
<thead>
<tr>
<th>15.15-16.15</th>
<th>NVDO/NASO</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>PS14:</strong> Adipose Tissue Biology II</td>
<td><strong>PS15:</strong> Cardiovascular Function and Biology II</td>
</tr>
<tr>
<td><strong>Chair:</strong> Kristiaan Wouters Het Binnenhof</td>
<td><strong>Chair:</strong> Ed Eringa Bibliotheque</td>
</tr>
<tr>
<td><strong>15.15-16.15</strong></td>
<td><strong>15.15-16.15</strong></td>
</tr>
<tr>
<td><strong>NVDO/NASO</strong></td>
<td><strong>NVDO/NASO</strong></td>
</tr>
<tr>
<td><strong>15.15-15.30:</strong> E. Nascimento (Maastricht)</td>
<td><strong>15.15-15.30:</strong> E. van Bommel (Amsterdam)</td>
</tr>
<tr>
<td>68. Genetic markers of brown adipose tissue (BAT) and in vitro BAT activity in humans</td>
<td>72. One-year Treatment with Exenatide Twice-Daily Does Not Affect Renal Function Decline or Albuminuria Compared to Insulin Glargine in Metformin-Treated Type 2 Diabetes Patients: A Randomised, Controlled Trial</td>
</tr>
<tr>
<td>15.30-15.45: K. Verboven (Maastricht)</td>
<td><strong>15.30-15.45:</strong> K. Thiem (Nijmegen)</td>
</tr>
<tr>
<td>69. Depot-specific adipose tissue morphology and inflammatory phenotype in obese insulin resistant and type 2 diabetic men</td>
<td>73. The role of C-type-Lectin receptors in hyperglycemia accelerated atherosclerotic plaque formation</td>
</tr>
<tr>
<td><strong>15.45-16.00:</strong> L. Tambyrajah (Leiden)</td>
<td><strong>15.45-16.00:</strong> L. van Tonneijck (Amsterdam)</td>
</tr>
<tr>
<td>70. Biological clock strongly regulates brown adipose tissue activity: implications for postprandial triglyceride metabolism</td>
<td>74. Postprandial Renal Effects of GLP-1 Receptor Agonist Lixisenatide versus Once-Daily Insulin Glulisine Added to Basal Insulin Glargine in Overweight Type 2 Diabetes Patients: an 8-Week, Randomised, Open-Label Trial</td>
</tr>
<tr>
<td><strong>16.00-16.15:</strong> Y. Wang (Leiden)</td>
<td><strong>16.00-16.15:</strong> L. Janssen (Leiden)</td>
</tr>
<tr>
<td>71. Butyrate prevents high fat diet-induced metabolic syndrome via inducing satiety and activating brown adipose tissue</td>
<td>75. HDL functionality in South Asians compared to white Caucasians</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>15.15-16.15</th>
<th>NVCD</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>PS8:</strong> NVCD (CNT’D)</td>
<td><strong>15.15-16.30 NVCD</strong></td>
</tr>
<tr>
<td><strong>Chair:</strong> Sicco Bus</td>
<td><strong>Chair:</strong> Sicco Bus</td>
</tr>
<tr>
<td>The Lacock Abbey</td>
<td>The Lacock Abbey</td>
</tr>
<tr>
<td><strong>15.15-15.30:</strong> T. Busch-Westbroek (Amsterdam)</td>
<td><strong>15.30-16.30:</strong> Charcot-Net Meeting</td>
</tr>
<tr>
<td>43. Effect of RANKL-antibody treatment in acute diabetic neuro-osteoarthropathy (Charcot foot)</td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>15.15-16.15</th>
<th>NVDO/NASO</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>PS16:</strong> Brain</td>
<td><strong>ALV NIV-Diabeteskamer</strong></td>
</tr>
<tr>
<td><strong>Chair:</strong> Bastiaan de Galan</td>
<td></td>
</tr>
<tr>
<td>The Oval Office</td>
<td></td>
</tr>
<tr>
<td><strong>15.15-15.30:</strong> C. Coomans (Leiden)</td>
<td><strong>15.15-16.15</strong></td>
</tr>
<tr>
<td>76. Doublecortin-like protein in hypothalamic tanycytes is involved energy homeostasis</td>
<td><strong>NVDO/NASO</strong></td>
</tr>
<tr>
<td><strong>15.30-15.45:</strong> H. Rooijackers (Nijmegen)</td>
<td><strong>PS16:</strong> Brain</td>
</tr>
<tr>
<td>77. High-intensity interval exercise reduces awareness of hypoglycemia in patients with type 1 diabetes</td>
<td><strong>15.15-16.15:</strong> M. van Agtmaal (Maastricht)</td>
</tr>
<tr>
<td><strong>15.45-16.00:</strong> M. van Agtmaal (Maastricht)</td>
<td>78. Prediabetes is associated with white matter abnormalities: the Maastricht study</td>
</tr>
<tr>
<td>79. Pre-transplant psychopathology predicts complications after simultaneous pancreas and kidney transplantation</td>
<td><strong>16.00-16.15:</strong> M. Ruissen (Leiden)</td>
</tr>
<tr>
<td><strong>16.00-16.15:</strong> M. Ruissen (Leiden)</td>
<td></td>
</tr>
<tr>
<td>79. Pre-transplant psychopathology predicts complications after simultaneous pancreas and kidney transplantation</td>
<td></td>
</tr>
</tbody>
</table>

**16.15-17.00 Snack break**
17.00-17.50 Gerritzen Award Ceremony for best thesis on diabetes research
   Chair: Eelco de Koning
17.00-17.05 Introduction by the chairman
17.05-17.20 Thesis Nominee A
17.20-17.35 Thesis Nominee B
17.35-17.50 Thesis Nominee C
17.50-18.05 Memorial Lecture

18.05-18.30 break

18.30-19.30 State-of-the-Art lecture
   Prof. Dr. Michael Roden;
   Tissue-specific differences in energy metabolism in type 2 diabetes and non-alcoholic fatty liver disease
   Chair: Matthijs Hesselink

19.30-19.45 Gerritzen Award Ceremony (cont’d)
19.30-19.35 Short address by award sponsor
19.35-19.40 Announcement of the winner of the 28th Gerritzen award
19.40-20.00 Drinks

20.00-01.00 Dinner, Gerritzen Party with music
### Friday 2 December 9.15-10.00 Parallel sessions

<table>
<thead>
<tr>
<th>09.15-10.00 NVDO/NASO</th>
<th>09.15-10.00 NVDO/NASO</th>
<th>09.15-10.00 NVDO/NASO</th>
<th>09.15-10.00 NVDO/NASO</th>
</tr>
</thead>
</table>

### Friday 2 December 10.00-10.45 Plenary Session

- **10.00-10.45 Plenary session: How to get your research funded**
  - Bilderberg I & II
  - 10.00-10.15: Diabetes Onderzoek Nederland (DON)
  - 10.15-10.30: Diabetes Fonds Nederland (DFN)
  - 10.30-10.45: Juvenile Diabetes Research Foundation (JDRF)
**Friday 2 December 10.45-11.15  Plenary Session**

<table>
<thead>
<tr>
<th>Time</th>
<th>Event</th>
</tr>
</thead>
<tbody>
<tr>
<td>10.45-11.15</td>
<td>Terpstra Award ceremony</td>
</tr>
<tr>
<td></td>
<td>Chair: Bastiaan de Galan</td>
</tr>
<tr>
<td></td>
<td>Zappeion/Megaron</td>
</tr>
<tr>
<td>10.45-11.00</td>
<td>Opening and Lecture By Kristiaan Wouters, Winner of the award in 2015</td>
</tr>
<tr>
<td>11.00-11.15</td>
<td>Announcement and lecture by the 2016 awardee</td>
</tr>
</tbody>
</table>

**Friday 2 December 11.45-13.30  Plenary Lecture & Best abstracts**

<table>
<thead>
<tr>
<th>Time</th>
<th>Event</th>
</tr>
</thead>
<tbody>
<tr>
<td>11.45-12.45</td>
<td>State-of-the-art-lecture II: Prof. Dr. Olle Korsgren: Novel insights in the etiology of Type 1 Diabetes with implications for future intervention trials</td>
</tr>
<tr>
<td></td>
<td>Chair: Marten Engelse</td>
</tr>
<tr>
<td></td>
<td>Zappeion/Megaron</td>
</tr>
</tbody>
</table>

**12.45-13.15 NVDO/NASO**

**BEST MEETING ABSTRACTS**

<table>
<thead>
<tr>
<th>Time</th>
<th>Event</th>
</tr>
</thead>
<tbody>
<tr>
<td>12.45-13.00</td>
<td>E. Wiegers (Nijmegen)</td>
</tr>
<tr>
<td></td>
<td>95. High-intensity interval training affects brain lactate levels during hypoglycemia in type 1 diabetes</td>
</tr>
<tr>
<td>13.00-13.15</td>
<td>K. ter Horst (Amsterdam)</td>
</tr>
<tr>
<td></td>
<td>96. Hepatic diacylglycerol-associated protein kinase C epsilon translocation links hepatic steatosis to hepatic insulin resistance in humans</td>
</tr>
<tr>
<td>13.15-13.30</td>
<td>K. van Galen (Amsterdam)</td>
</tr>
<tr>
<td></td>
<td>97. Methods for quantifying adipose tissue insulin resistance in humans</td>
</tr>
</tbody>
</table>

**13.30-14.00 Farewell lunch**